Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Depomed has sued Sun Pharmaceutical Industries for violating patents related to its 500mg and 1000mg Glumetza (metformin hydrochloride extended release tablets) in the US District Court for the District of New Jersey.
Subscribe to our email newsletter
The lawsuit was filed in connection with Sun Pharma‘s submission of abbreviated new drug application (ANDA) seeking marketing rights for the generic versions of Depomed‘s 500mg and 1000mg strengths of Glumetza before the expiration of the five US patents: 6,340,475, 6,488,962, 6,635,280, 6,723,340, and 7,780,987.
Depomed has filed the suit within 45 days required to stay, or bar, the FDA from approving Sun Pharma’s ANDA for 30 months or until a district court decision that is adverse to the patents, whichever may occur earlier.
Depomed senior vice president and general counsel Matthew Gosling said Depomed will continue to vigorously enforce its intellectual property rights with respect to their Glumetza products.